Company intelligence / Profile preview

Reprieve Cardiovascular

Milford, Massachusetts, United Statesreprievecardio.com ↗

Ownership: Private
Development stage: Other

Overview

The FASTR randomized pilot study demonstrated that the Reprieve System significantly improved sodium excretion, total urine output, and weight loss compared to optimal diuretic therapy in patients with ADHF. The system met both primary efficacy and safety endpoints without increasing adverse events. FDA approval has been granted for a pivotal IDE trial ("FASTR II") now launching in the US and Europe.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically, an automated fluid management system for heart failure)Non-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Over 150 healthcare provider partnerships across the United States to facilitate adoption of its therapies into standard care protocols

Beyond the preview

Go deeper on Reprieve Cardiovascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reprieve Cardiovascular.